|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.590 SEK | -0.12% |
|
-3.37% | -36.37% |
| 07:13am | Vivesto Completes Enrollment in Canine Study | FW |
| 06-16 | Vivesto AB Reports Positive Results From Intravenous Cantrixil Pharmacokinetic And Toxicology Study | CI |
| Market Cap | 95.21M 9.81M 8.61M 7.94M 7.42M 13.92M 925M 14.17M 36.88M 456M 36.82M 36.02M 1.59B | P/E 2026 * |
-2.81x | P/E 2027 * | -2.05x |
|---|---|---|---|---|---|
| Enterprise Value | 87.21M 8.98M 7.89M 7.27M 6.8M 12.75M 848M 12.98M 33.78M 418M 33.73M 32.99M 1.45B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
56.4% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Vivesto AB
| 1 day | -0.12% | ||
| 1 week | -3.37% | ||
| Current month | -20.02% | ||
| 1 month | -30.50% | ||
| 3 months | +3.25% | ||
| 6 months | -38.99% | ||
| Current year | -36.37% |
| 1 week | 8.44 |  | 9 |
| 1 month | 8.31 | | 12.36 |
| Current year | 7 | | 19.5 |
| 1 year | 7 | | 31.9 |
| 3 years | 7 | | 90.6 |
| 5 years | 7 | | 319 |
| 10 years | 7 | | 1,670 |
| Manager | Title | Age | Since |
|---|---|---|---|
Erik Kinnman
CEO | Chief Executive Officer | 68 | 22/01/2023 |
Robert Maiorana
DFI | Director of Finance/CFO | 66 | 30/06/2022 |
| Chief Tech/Sci/R&D Officer | 39 | 31/12/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 46 | 24/05/2022 | |
Hege Hellstrom
BRD | Director/Board Member | 61 | 25/09/2019 |
Pål Ryfors
BRD | Director/Board Member | 43 | 24/05/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 24/03/22 | Buy | Chief Executive Officer | 12,200 | 0.0027% | ||
| 23/03/22 | Others | Chairman | 120,000 | 0.0268% | ||
| 19/12/21 | Free | Chief Executive Officer | 2,250,000 | 0.5018% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.12% | -3.37% | -62.24% | -71.32% | 9.81M | |
| +6.16% | +5.72% | +46.54% | +157.34% | 1,006B | |
| +3.60% | +8.39% | +64.93% | +53.21% | 589B | |
| +1.92% | +7.39% | +32.24% | +83.04% | 430B | |
| -0.67% | +5.11% | +29.26% | +21.27% | 331B | |
| +1.11% | +6.30% | +38.69% | +24.59% | 288B | |
| -0.06% | +5.78% | +30.33% | +40.73% | 285B | |
| -0.40% | +6.32% | -27.73% | -42.06% | 213B | |
| +2.54% | +3.66% | +28.03% | +59.01% | 190B | |
| +3.29% | +1.11% | +17.31% | +64.90% | 154B | |
| Average | +1.73% | +4.97% | +19.73% | +39.07% | 348.58B | |
| Weighted average by Cap. | +2.87% | +5.38% | +37.43% | +75.52% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -31M -3.19M -2.8M -2.58M -2.42M -4.53M -301M -4.61M -12.01M -148M -11.99M -11.73M -516M | -46M -4.74M -4.16M -3.83M -3.58M -6.72M -447M -6.85M -17.82M -220M -17.79M -17.4M -766M |
| Net Debt | -8M -824K -724K -667K -623K -1.17M -77.74M -1.19M -3.1M -38.32M -3.09M -3.03M -133M | -10M -1.03M -905K -833K -779K -1.46M -97.18M -1.49M -3.87M -47.9M -3.87M -3.78M -166M |
Employees
4
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/06/26 | SEK 8.590 | -0.12% | 4,619 |
| 25/06/26 | SEK 8.600 | -3.15% | 4,945 |
| 24/06/26 | SEK 8.880 | -0.22% | 24,582 |
| 23/06/26 | SEK 8.900 | +0.11% | 20,265 |
| 22/06/26 | SEK 8.890 | -0.67% | 10,238 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- VIVE Stock
Select your edition
All financial news and data tailored to specific country editions
